Biotech Business - February 2, 2026
Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand
Alvotech has entered into supply and commercialization agreements with Sandoz covering multiple biosimilar candidates in Canada, and in Australia and New Zealand.
New Market - January 12, 2026
Novo Nordisk’s Wegovy pill now broadly available across America
Wegovy pill was approved on December 22, 2025 and is used with a reduced calorie diet and increased physical activity for adults with obesity, or with overweight who also have weight-related medical problems, to help them lose weight and keep it off.
Biotech Business - January 2, 2026
Alvotech announces European launch of first-in-market biosimilar to Simponi
Alvotech has announced that launches are underway in Europe for Gobivaz (golimumab), Alvotech’s biosimilar to Simponi (golimumab), also known as AVT05 (prefilled syringe and autoinjector).
Biotech Business - December 9, 2025
Leqembi included in China’s commercial insurance innovative drug list
BioArctic’s partner Eisai has announced that Leqembi (lecanemab), has been included in the “Commercial Insurance Innovative Drug List”, recently introduced by the National Healthcare Security Administration (NHSA) of China.
New Market - December 9, 2025
Cinclus Pharma’s linaprazan glurate earns China’s National Reimbursement Listing
Cinclus Pharma Holding's drug linaprazan glurate has been included in China’s 2025 National Reimbursement Drug List (NRDL) for the treatment of gastroesophageal reflux disease (GERD).
Biotech Business - November 24, 2025
Alvotech receives European approval of a biosimilar to Prolia and Xgeva
“This milestone reflects not only the dedication and expertise of our teams, but also the strong partnerships we have built to bring affordable medicines to patients across Europe,” says Robert Wessman, Chairman and Chief Executive Officer of Alvotech.
